Multiple Sclerosis Disability Progression Linked to NfL Biomarker

The researchers looked at the incidence of disability worsening, defined as six months or more of increased impairment reflected in a higher score on the Expanded Disability Status Scale, in the study, which has been published in JAMA Neurology. They differentiated between disability increasing with recurrence, which includes remaining symptoms or the return of old ones after relapse, and progressive advancement of symptoms without relapse.

91% of Patients with Multiple Sclerosis are at High Risk of Disability

The researchers analyzed data from around 4,000 patient visits to UCSF in the EPIC study and nearly 9,000 patient visits to different sites in Switzerland in the SMSC study over 10 years. The two investigations involved over 1,900 patients in total. 570 people were recognized as having a disability that was worsening, with the majority being independent of relapses.

Researchers discovered that elevated NfL levels were related to a 91% greater chance of deteriorating impairment with relapse almost a year later, and a 49% higher risk of worsening disability without relapse nearly two years later.

NfL Blood Marker Linked to Worsening of Multiple Sclerosis

“We think that NfL elevation occurs earlier in disability worsening without relapse,” said Abdelhak. This different pattern may indicate “a more prolonged process that decreases in intensity in advance of increased impairment,” said co-senior author Ari Green, M.D., medical director of the UCSF Multiple Sclerosis and Neuroinflammation Center. “This aligns with the recognition that death of nerve cells is a slow process that builds toward permanent disability and means that interventions to protect nerve cells might have time to also stop disability,” he said.

“In addition to the groundbreaking findings on the temporal relationship between NfL increases and gradual disease progression in MS, the study supports the important role of NfL as an early marker of nerve damage,” said co-senior author Jens Kuhle, M.D., Ph.D., who led the Swiss cohort and is head of the Multiple Sclerosis Center at University Hospital and University of Basel, Switzerland. “Monitoring NfL levels might be able to detect disease activity with higher sensitivity than clinical exam or conventional imaging,” he said.

Future research will explore into therapies that can halt progression during this phase of high NfL.

References:

1. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis
   
   doi:10.1001/jamaneurol.2023.3997
2. The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs
   
   Bebo B, Cintina I, LaRocca N, Ritter L, Talente B, Hartung D, Ngorsuraches S, Wallin M, Yang G. The Economic Burden of Multiple Sclerosis in the United States: Estimate of Direct and Indirect Costs. Neurology. 2022 May 3;98(18):e1810-e1817. doi: 10.1212/WNL.0000000000200150. Epub 2022 Apr 13. PMID: 35418457; PMCID: PMC9109149.

Source: Medindia